SCHEMBL2437272

SCHEMBL2437272

COC(=O)Nc1cc(Oc2ccc3c(C(=O)Nc4ccc(CN5CCN(C(C)C)CC5)c(C(F)(F)F)c4)nccc3c2)ncn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCK P08631 12/20 0.53
SRC P12931 4/20 0.53
MKNK2 Q9HBH9 3/20 0.53
ABL1 P00519 3/20 0.53
MKNK1 Q9BUB5 2/20 0.53
MAP3K7 O43318 2/20 0.53
FES P07332 2/20 0.53
FER P16591 2/20 0.53
MAP4K2 Q12851 2/20 0.53
MAPK14 Q16539 2/20 0.53
AXL P30530 2/20 0.53
FLT3 P36888 2/20 0.53
MERTK Q12866 2/20 0.53
CDK2 P24941 2/20 0.53
CDK8 P49336 2/20 0.53
STK25 O00506 1/20 0.53
CIT O14578 1/20 0.53
MAP2K7 O14733 1/20 0.53
IKBKB O14920 1/20 0.53
AURKA O14965 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2434445 0.94 HCK (0.54) HCKSRCMKNK2ABL1MKNK1
SCHEMBL2434003 0.93 HCK (0.55) HCKSRCMKNK2ABL1MKNK1
SCHEMBL2434299 0.92 SRC (0.51) HCKSRCMKNK2ABL1MKNK1
SCHEMBL2434611 0.90 KDR (0.53) HCKSRCMKNK2ABL1MKNK1
SCHEMBL2435174 0.87 HCK (0.56) HCKSRCMKNK2ABL1MKNK1
SCHEMBL2435267 0.84 CDK2 (0.58) HCKSRCMKNK2ABL1MKNK1
SCHEMBL2433219 0.84 KDR (0.54) HCKSRCMKNK2ABL1MKNK1
SCHEMBL2435727 0.82 KDR (0.56) HCKSRCMKNK2ABL1MKNK1
SCHEMBL3309711 0.82 CDK8 (0.62) HCKSRCABL1MAP3K7MAP4K2
SCHEMBL2433730 0.80 SRC (0.57) HCKSRCMKNK2ABL1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 US disclosed
US-8026247-B2 Bicyclic amides as kinase inhibitors NOVARTIS AG (CH) 2011-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 HCK 439/4885SRC 353/4885MKNK2 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.